Abstract

 Clinical evidence suggests that Dupixent should be reimbursed to treat patients aged 12 years and older with severe asthma and with a type 2 or eosinophilic phenotype or oral corticosteroid–dependent asthma.
 Economic evidence suggests that a 93% price reduction is needed to ensure Dupixent is cost-effective at a $50,000 per quality-adjusted life-year threshold relative to standard of care alone.
 Cost-effectiveness versus other biologics is unknown.
 CADTH was unable to estimate the budget impact due to a high degree of uncertainty.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
